Enrique Conterno (Credit: Duke University Fuqua School of Business via YouTube)
May 10, 2022 10:39 AM EDT
R&D
Pharma

Fi­bro­Gen CEO: Roxa path blocked as As­traZeneca re­mains un­de­cid­ed on just what it plans to do in the wake of a CRL

John Carroll

Editor & Founder

Fi­bro­Gen CEO En­rique Con­ter­no hasn’t giv­en up on the US mar­ket when it comes to their ane­mia drug rox­adu­s­tat. But with As­traZeneca ex­ecs re­fus­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times